AbSci to go public as IPO prices in middle of expected range, valuing company at more than $1.4 billion
AbSci Corp.
ABSI,
is headed for its public debut Thursday, after the Washington-based provider of an artificial intelligence-powered drug creation platform said overnight that its IPO priced at $16 a share, in the middle of the expected range. The company…
